The randomised trial saw more than half of patients dosed with Sunosi achieving clinical response to the therapy used to ...

KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat for hereditary angioedema ...

While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in ...

Helicore Biopharma has dosed the first subject in the randomised first-in-human Phase I trial of HCR-188 to treat obesity.

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face ...

Entrada Therapeutics has secured authorisation from the UK MHRA to commence Phase I/II trial of ENTR-601-45 for treating DMD.

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...

Mural Oncology’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over ...

Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

Today marks World TB Day 2025 with the WHO calling for more investment into TB treatment and research globally.